Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Total 13F shares
-
72,260,806
-
Share change
-
+3,558,359
-
Total reported value
-
$1,300,999,134
-
Put/Call ratio
-
41%
-
Price per share
-
$18.00
-
Number of holders
-
182
-
Value change
-
+$58,157,061
-
Number of buys
-
107
-
Number of sells
-
62
Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q4 2019
As of 31 Dec 2019,
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) was held by
182 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,260,806 shares.
The largest 10 holders included
Temasek Holdings (Private) Ltd, BlackRock Inc., STATE STREET CORP, JPMORGAN CHASE & CO, VANGUARD GROUP INC, LORD, ABBETT & CO. LLC, Kohlberg Kravis Roberts & Co. L.P., WELLINGTON MANAGEMENT GROUP LLP, ALLIANCEBERNSTEIN L.P., and Rubric Capital Management LP.
This page lists
183
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.